Author:
Luo Yanping,Hradil Vincent P.,Frost David J.,Rosenberg Saul H.,Gordon Gary B.,Morgan Sherry J.,Gagne Gerard D.,Cox Bryan F.,Tahir Stephen K.,Fox Gerard B.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology (medical),Pharmacology,Oncology
Reference55 articles.
1. Anti-angiogenic therapy as a cancer treatment paradigm;Dhanabal;Curr Med Chem Anticancer Agents,2005
2. Antiangiogenesis, anti-VEGF(R) and outlook;Petersen;Recent Results Cancer Res,2007
3. Antiangiogenesis for cancer therapy;Harris;Lancet,1997
4. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors;Schlaeppi;Cancer Metastasis Rev,1999
5. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration;Wood;Cancer Res,2000
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献